NO992212L - Identifisering av enestaende bindingsinteraksjoner mellom spesielle antistoff og de humane B7.1- og B7.2-kostimulatoriske antigener - Google Patents

Identifisering av enestaende bindingsinteraksjoner mellom spesielle antistoff og de humane B7.1- og B7.2-kostimulatoriske antigener

Info

Publication number
NO992212L
NO992212L NO19992212A NO992212A NO992212L NO 992212 L NO992212 L NO 992212L NO 19992212 A NO19992212 A NO 19992212A NO 992212 A NO992212 A NO 992212A NO 992212 L NO992212 L NO 992212L
Authority
NO
Norway
Prior art keywords
antibodies
identification
human
binding interactions
particular antibodies
Prior art date
Application number
NO19992212A
Other languages
English (en)
Norwegian (no)
Other versions
NO992212D0 (no
Inventor
Darrell R Anderson
Cheryl Heard
Nabil Hanna
Peter Brams
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO992212D0 publication Critical patent/NO992212D0/no
Publication of NO992212L publication Critical patent/NO992212L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
NO19992212A 1996-11-08 1999-05-06 Identifisering av enestaende bindingsinteraksjoner mellom spesielle antistoff og de humane B7.1- og B7.2-kostimulatoriske antigener NO992212L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74636196A 1996-11-08 1996-11-08
PCT/US1997/019906 WO1998019706A1 (fr) 1996-11-08 1997-10-29 Identification d'interactions de liaison uniques entre certains anticorps et les antigenes costimulants b7.1 et b7.2 humains

Publications (2)

Publication Number Publication Date
NO992212D0 NO992212D0 (no) 1999-05-06
NO992212L true NO992212L (no) 1999-07-08

Family

ID=25000516

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19992212A NO992212L (no) 1996-11-08 1999-05-06 Identifisering av enestaende bindingsinteraksjoner mellom spesielle antistoff og de humane B7.1- og B7.2-kostimulatoriske antigener

Country Status (14)

Country Link
EP (2) EP1878748A2 (fr)
JP (3) JP4048294B2 (fr)
KR (1) KR100510604B1 (fr)
CN (1) CN1198646C (fr)
AT (1) ATE453406T1 (fr)
AU (1) AU739058B2 (fr)
BR (1) BR9713498A (fr)
CA (1) CA2270922A1 (fr)
DE (1) DE69739725D1 (fr)
HK (1) HK1025741A1 (fr)
ID (1) ID21676A (fr)
NO (1) NO992212L (fr)
RU (1) RU2221590C2 (fr)
WO (1) WO1998019706A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
CN1068524C (zh) * 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
CZ20012925A3 (cs) 1999-02-12 2002-01-16 Genetics Institute, Inc. Humanizovaný imunoglobulin reaktivní s B7 molekulami a způsob léčení
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
AU2001264747A1 (en) * 2000-05-22 2001-12-03 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
EP1372724A2 (fr) * 2001-01-31 2004-01-02 Idec Pharmaceuticals Corporation Anticorps immunoregulateurs et ses utilisations
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
AU2002346373A1 (en) * 2001-11-09 2003-05-19 Idec Pharmaceuticals Corporation Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20040152105A1 (en) * 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
CN101068574B (zh) * 2004-07-20 2012-07-18 伊索格尼斯股份有限公司 与自身抗原有关的自身免疫和疾病的特异性抑制
CN1817909B (zh) * 2005-02-08 2010-08-11 复旦大学 一种双功能融合蛋白
CN100369931C (zh) * 2005-04-07 2008-02-20 苏州大学 抗人b7-1分子单克隆抗体及其应用
CN117534755A (zh) * 2005-05-09 2024-02-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
CA2795789A1 (fr) 2010-04-09 2011-10-13 Amgen Inc. Proteines btnl9, acides nucleiques, et anticorps et leurs utilisations
US9567367B2 (en) * 2012-01-16 2017-02-14 Atox Bio Ltd. Synthetic peptides for treatment of bacterial infections
CZ306905B6 (cs) 2013-06-11 2017-09-06 Česká zemědělská univerzita v Praze Způsob pro stanovení vodní hodnoty sněhu sněhové vrstvy a zařízení pro provádění tohoto způsobu
CN106177931B (zh) * 2016-08-25 2018-02-02 河北浓孚雨生物科技有限公司 免疫检测点双阻断ctl高效率杀伤细胞制剂的制备方法
US20220025051A1 (en) 2018-12-07 2022-01-27 Ono Pharmaceutical Co., Ltd. Immunosuppresive agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies

Also Published As

Publication number Publication date
KR20000053137A (ko) 2000-08-25
AU5100998A (en) 1998-05-29
KR100510604B1 (ko) 2005-08-31
EP1878748A2 (fr) 2008-01-16
CN1198646C (zh) 2005-04-27
JP2009001570A (ja) 2009-01-08
ID21676A (id) 1999-07-08
WO1998019706A1 (fr) 1998-05-14
BR9713498A (pt) 2000-02-29
EP1007090A4 (fr) 2001-03-14
EP1007090B1 (fr) 2009-12-30
ATE453406T1 (de) 2010-01-15
HK1025741A1 (en) 2000-11-24
JP4320381B2 (ja) 2009-08-26
DE69739725D1 (de) 2010-02-11
CN1244128A (zh) 2000-02-09
NO992212D0 (no) 1999-05-06
JP2001504693A (ja) 2001-04-10
EP1007090A1 (fr) 2000-06-14
RU2221590C2 (ru) 2004-01-20
JP2007330261A (ja) 2007-12-27
JP4048294B2 (ja) 2008-02-20
AU739058B2 (en) 2001-10-04
CA2270922A1 (fr) 1998-05-14

Similar Documents

Publication Publication Date Title
NO992212L (no) Identifisering av enestaende bindingsinteraksjoner mellom spesielle antistoff og de humane B7.1- og B7.2-kostimulatoriske antigener
DK0892643T3 (da) Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
Koulova et al. The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells.
NO963018L (no) CTLA4-mutantmolekyler og anvendelser derav
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
AU2003288675A8 (en) Antibodies against PD-1 and uses therefor
GB9022011D0 (en) Chimaeric antibodies and their preparation
DE69935318D1 (de) Immununterdrückung durch blockierung des t-zellencostimulierungssignales 2 (b7/cd28 interaktion)
NO951212D0 (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
DK0955995T3 (da) Anvendelse af komplekser til fremstilling af præparater til behandling af sensibel hud, fremgangsmåde til fremstilling af hypoallergene præparater
WO2000023053A3 (fr) Procede d'isolement, de quantification, de caracterisation et de modulation de cellules specifiques d'antigenes
MXPA02012157A (es) Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
FI930207A (fi) Anordning foer diagnostisk testning av hud
Solana et al. Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands
Ha et al. Aggressive skin allograft rejection in CD28−/− mice independent of the CD40/CD40L costimulatory pathway
EP0876397A4 (fr) Antigenes de rejet tumoral presentes par des molecules hla-b44 et utilisations de ces derniers
Cloud Exorcising an old demon.
Hämmerling et al. Cellular expression of Ia antigens and their possible role in immune reactions
Olack et al. The role of indirect antigen recognition in islet xenograft rejection
Carney The dark forces.
Lamousé-Smith et al. Cytokine requirements for production of a novel anti-CD8-resistant CTL population
Meuer Adhesion molecules: receptors dictating local immune responses
Waller et al. Don't ask, don't treat.
HoWangYin et al. Trogocytosis and NK Cells in Mouse and Man
Kavanaugh Necessary things.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application